Evidence has been accumulating ever since the advent of
combination antiretroviral therapy that people with suppressed or undetectable
HIV viral loads, especially those on therapy, are a great deal less likely to
transmit HIV than untreated persons.
In the last two years, two pivotal studies in heterosexual
couples where one of the partners has HIV have demonstrated that HIV-positive
people who are on antiretroviral (ARV) treatment are about 20 times less likely
to transmit the virus to their partners than people who are not taking
treatment.
First, in February 2010, the Partners in Prevention study,
which was designed to find out if treating herpes might reduce HIV
transmission, found that the minority of its participants who started taking
ARVs were 92% less likely to transmit HIV to their partners once they started
therapy.1
However Partners in Prevention was not a randomised controlled trial of the
prevention potential of ARV treatment and so it could not prove beyond a shadow
of doubt that this was the true reduction in risk.
The definitive proof came in May 2011 when the HPTN 052 study was stopped three years earlier
than planned. This study randomised the positive partner in heterosexual
couples either to start taking ARVs immediately, at an average CD4 count of 436
cells/mm3, or to delay taking them till their CD4 count fell below
250 cells/mm3.
The study found that people on treatment were 96% less
likely to transmit HIV to their partners than untreated people. Michel Sidibé,
the Executive Director of UNAIDS, commented that, “This breakthrough is a
serious game changer and will drive the prevention revolution forward. It makes
HIV treatment a new priority prevention option.”2
HPTN 052 shows that, if a sufficiently large proportion of
the HIV-positive population could be treated and their viral loads brought down
to an undetectable level, transmission might become rare enough for the
epidemic to stop in its tracks.
On a population level this can be expressed as a
reduction in the ‘community viral load’, the viral load averaged over the
whole population, a term first coined in a paper from San Francisco in 2004.3
This paper suggested a new approach to HIV prevention. At
the start of the epidemic the only proven ways to reduce the risk of infection
were needle-exchange programmes, the provision of condoms (and female condoms
from 1993 on), and behaviour-change programmes to reduce sexual risk and
encourage the use of condoms. With the exception of needle exchange these have
all had limited, and unpredictable, success.
Since then two approaches were scientifically proven to
reduce HIV infection, but they can only benefit certain sections of the
population. One is the prevention of mother-to-child transmission, a largely
ARV-based strategy which started to be adopted in the late 1990s. The other is
male circumcision which, though proven to be effective in 2005, is only of
immediate benefit to heterosexual men (though female partners will benefit in
the longer term) and is only likely to help reduce HIV incidence on a
population level in countries with generalised epidemics.
Evidence for the use of ARVs as prevention methods in
HIV-negative people, either as orally-dosed pre-exposure prophylaxis (PrEP) or as
a topical microbicide, has been strengthened by positive results from the
CAPRISA 004 study of a tenofovir gel microbicide for women4 and the iPrEx study of oral
tenofovir/FTC as PrEP in gay men.5 However the overall
efficacies demonstrated (39% in CAPRISA and 43% in iPrEx) were not enough for
the use of these methods to be licensed without question. The studies made it clear that a number of
advances in formulation, adherence support and user targeting would need to be
made if they are going to be widely adopted.
Disappointment in the field of vaccine research showed that
developing a vaccine against a retrovirus like HIV will, at the very least,
require fundamentally new technologies.
Until now, the
epidemic has therefore lacked a generally applicable biomedical prevention
method which is less dependent on the vagaries of human sexual behaviour than
barrier methods.
In the last four to five years,
however, mass treatment of people with HIV as a prevention method has
gained credibility as a way of stopping or slowing the epidemic.
Previous to this, there were a number of reasons why it was
not seen as viable:
- The
available ARVs, especially the cheaper ones used mainly in the
lower-income world such as d4T, were sufficiently toxic that providing
them to people with high CD4 counts who were not in immediate clinical
need was likely to do more harm than good.
- Viral-suppression
rates were less than 80% in 2000 even in patients with near-perfect
adherence.6
These improved with the advent of boosted protease inhibitors, but were
still only in the order of 80-85%. For this reason, and because of fear
that people with high CD4 counts might have poorer adherence, there was
concern (and some mathematical models appeared to show) that
population-based ARV provision risked generating huge amounts of
drug-resistant HIV.
- Even
providing ARVs to stop people dying of AIDS has required an unprecedented expansion of health
programmes and funding for them in lower-income countries, and is
expensive even in richer ones. In the absence of strong cost-benefit data,
population-wide ARV provision was seen as financially unviable.
Several developments,
however, even before the Partners in Prevention and HPTN 052 results, had
contributed to making population-level ARV provision seem more effective and
feasible as a strategy:
- In
2006 the SMART study7
found that patients who kept taking ARVs at CD4 counts of over 350 cells/mm3
were about half as likely to die as those who stopped. This result,
unexpected at the time, reset the perceived risk/benefit ratio for taking
HIV treatment in favour of taking it. Other studies have since confirmed
this, with some finding that the benefit of taking HIV therapy applies
even to people with CD4 counts over 500 cells/mm3.8 Newer-generation HIV drugs like
tenofovir and some of the newer protease inhibitors appear less toxic than
the previous-generation drugs such as d4T, AZT and indinavir, and are less
associated with stigmatising fat-redistribution effects.
- Rates
of viral suppression seen in people taking ARVs are now in the region of
90% or more in many settings,9
and HIV drug resistance has become considerably rarer as the number of
people taking ARVs with an incompletely suppressed viral load has fallen.10
- Although
universal provision of antiretrovirals is still a very ambitious goal,
especially in the context of global recession when clinical ARV drug
programmes in lower- and middle-income countries are facing rationing,11 the achievement of high treatment coverage for those in clinical
need in countries such as Botswana
has made universal coverage at least seem within the realm of possibility.
- Studies
have provided evidence that people taking antiretrovirals are more than
ten times less likely to transmit HIV to their partners than those not on
treatment.1
This means that HAART has the highest efficacy so far seen for any ‘real-world’
HIV-prevention intervention. (Condoms have 95-99% efficacy in ideal use,
but in real-world settings 100% attempted use has an efficacy of no more
than 85% - see Condoms and lubricants.)
- There
is some tentative evidence that the reduction in infectiousness at a
population level produced by very high ARV coverage rates in some
communities has started to produce declines in HIV incidence.12,13
A peripheral
development, though one that signalled an important shift in thinking in HIV
prevention, was the issuing of a statement by the Swiss Federal AIDS Commission
(SFAC) in January 2008.14 What is now known as the
“Swiss Statement” was the first time a group of clinicians had given backing to
something that was already suspected to be the case amongst certain sections of
the HIV-affected community. This was that, under certain carefully defined
conditions, some people with undetectable viral loads were essentially
uninfectious.
This statement has
been revised and qualified since then, but although it was issued primarily in
reaction to the criminal prosecution for ‘HIV exposure’ (i.e. a person with HIV
having unprotected sex, even with disclosure of HIV status) of people who were
on antiretrovirals, it served to raise awareness within the HIV community and
elsewhere that ARVs could profoundly reduce the likelihood of someone
transmitting HIV. However it also caused alarm amongst some people who felt it
might serve as justification for abandoning safer sex.
Moreover, in 2006, Julio Montaner and his team from the
British Columbia Centre for Excellence in HIV/AIDS had published an article in The Lancet15
that used a mathematical model to forecast that providing antiretroviral
therapy to every HIV-positive person in the world would stop the HIV epidemic
within 50 years at an average cost of $7 billion a year. At the time, this
model attracted relatively little attention and was primarily seen as an
advocacy tool.
However, when, in 2008, after the release of the Swiss
Statement, the same team published an article in the Journal of Infectious Diseases applying the same mathematical model
to British Columbia alone, and predicting that immediate and considerable
declines in HIV diagnosis would follow from a 50-100% increase in ARV coverage,16
the Health Minister of the province announced a new, aggressive policy of
diagnosing and treating the maximum number of individuals possible in order to
reduce the HIV-infection rate.
This was the first public endorsement of a strategy that is
sometimes called ‘Universal Test and Treat’ (UTT). The part of the strategy that
requires an expansion in testing and diagnosis is described in ‘The Role of HIV
Testing in HIV Prevention’.
In January 2009, the World Health Organization published its
own mathematical model, based on the British Columbia one, that calculated that
HIV transmission could be virtually eliminated by 2020 in countries with high
levels of HIV prevalence, such as South Africa, if it were possible to persuade
everyone in the community to test for HIV infection once a year and then
provide antiretroviral therapy to all who tested HIV-positive.17
This model caused considerable controversy amongst experts,
both in terms of the practicality of putting anything like universal testing
and treatment into practice, and also from human rights activists who were
concerned that such programmes could become coercive. The controversy was such
that the WHO hosted a consultation in November 2009 (see www.who.int/hiv/events/artprevention/en/index.html) to look at the issues of
implementing expanded testing and treatment.
Subsequent work at Imperial College, London has
refined the WHO’s rather simple model, finding that in some circumstances,
where the rate of sexual mixing and partner change is not too high, universal
treatment would not necessarily be required but that treating in accordance
with BHIVA and EACS guidelines and testing every four or five years would be
sufficient to produce an 85% reduction in new infections.18
However, this model was extremely sensitive to sexual
behaviour - much higher and probably unrealistic rates of testing and treatment
would be needed for populations with high rates of sexual-partner change.
These models have not
been received with universal approval by some HIV and prevention activists.
Some pointed out that the evidence backing up the treatment-as-prevention model
is weak and that several crucial areas are under-researched.
These include:
- whether
we need to gather more evidence on the long-term toxicities of ARVs before
making final decisions on long-term universal treatment programmes
- whether
someone with a sufficiently low blood viral load can ever be considered
completely uninfectious. People who are ‘undetectable’ by standard tests
actually maintain a persistent blood viral load averaging about three copies/ml19
- whether
blood plasma viral load is correlated enough with viral load in sexual
fluids to guarantee that a viral load test is a true indicator of
infectiousness
- whether
expanded treatment would reduce transmission via anal sex as much as it
would via vaginal sex
- the
exact degree to which sexually transmitted infections exacerbate HIV
infectiousness and whether treating them reduces infectiousness
- whether
expanding treatment might take too much attention away from research into,
and advocacy for, other HIV-prevention methods and programmes
- whether
increasing risk behaviour by people believing they, or their partners, are
non-infectious might cancel out any benefits
- whether
people in relatively good health will be sufficiently motivated to adhere
to long-term treatment
- the
role played in the epidemic by transmission from people in primary HIV
infection, who are less likely to be diagnosed
- the
overall practicality and cost effectiveness of upscaling testing and
treatment in this way.
Concerns were also expressed that over-promotion of the
concept might lead to compulsory or coercive testing and treatment programmes
in countries with authoritarian governments, and that the WHO and other
modellers had underestimated the importance of HIV stigma as a disincentive to
test.20 The WHO conducted its
own consultation in 2009 to discuss some of these issues.
Evidence that widespread antiretroviral coverage is starting
to bring down HIV prevalence and incidence is hard to find. This is not because
the concept is inherently flawed. It is because the proportion of the HIV
population that needs to be diagnosed and treated in order to bring down the
community viral load sufficiently far to make a difference is so high that it
has rarely been achieved anywhere.
Situations of falling HIV incidence have generally been ones
where a population spontaneously, or in response to campaigns, curbs its own
behaviour risk. Falls in incidence may take a long time to translate into falls
in prevalence.
(Prevalence is the proportion of the population who, at a
specific time, have the disease: so, for instance, if HIV prevalence in a
population is 12.5%, then one in every eight people has it. Incidence is the
rate of infection: the proportion of people who develop the disease within a
specific time frame. In a chronic disease like HIV this is usually expressed as
the number of infections per 100 people per year (or per, say, 100,000 for a
rarer condition). So in a community with an annual HIV incidence of 2%, then
one in every 50 people would be infected with HIV in a year.)
Initially, testing more people for HIV and putting more of
them on successful ARV treatment will tend to produce a rise in HIV prevalence.
In places where there has been high AIDS-related mortality, this is because the
death rate starts to fall faster than the infection rate, and more people
survive to infect others. In developed-world settings, where the new diagnosis
rate currently far exceeds the death rate in people with HIV, prevalence will
inevitably tend to rise, at least until large numbers of people with HIV start to
reach the age at which deaths start to match diagnoses, unless a very high
proportion of the population is virally suppressed. It will be even harder to
reduce prevalence if a rise in the proportion of people who are virally
suppressed is accompanied by a rise in the proportion having risky sex.
The UK
is a good example of a country with a relatively high rate of diagnosis and
very high rates of successful viral suppression, but where HIV prevalence has
nonetheless continued to climb inexorably. Another is the city of Washington, DC where a
nearly fivefold expansion in testing in the last five years has led to a 20%
rise in new diagnoses.21
However, in populations with very high testing rates, a low
proportion of people with HIV who are undiagnosed, and very high levels of ARV
coverage and viral suppression, the effect of reducing the community viral load
can start to be seen. The best evidence we have so far appears to come from San Francisco. Here
amongst gay men, which in this city form 85 to 90% of the HIV-positive population,
frequent testing, a low rate of undiagnosed cases, and high rates of ARV
coverage have produced a 40% fall in the community viral load between
2004-2008, a fall in new diagnoses of 45%, and what appears to be a 33% decline
in HIV incidence between 2006-2008, though as yet this has not reached
statistical significance.22 Similar falls have been
seen as a result of an intensive testing and prevention campaign amongst
injecting drug users in Vancouver,
British Columbia, though this has
not as yet been seen to be happening in the rest of the province.13
In March 2010, San Francisco
became the second area after British
Columbia to officially adopt a policy of aggressive
expansion of testing, especially for underserved populations, and universal
treatment regardless of CD4 count for those diagnosed.23,24 Epidemiologists in Switzerland
have urged the provision of early, continuous antiretroviral therapy for
sexually active HIV-positive gay men in the country.25